股票/基金 实时行情 股吧

简称:昭衍新药 代码:603127


会计年度:2018-12-31收入分布
项目名称主营业务收入主营业务成本主营业务毛利毛利率
合计408,798,150.01192,050,503.54216,747,646.4753.02
其他(补充)1,247,641.50793,259.16454,382.3436.42
实验动物及附属产品销售业务4,872,055.003,515,753.101,356,301.9027.84
药物警戒服务157,701.87473,562.97-315,861.10-200.29
药物临床前研究服务402,520,751.64187,267,928.31215,252,823.3353.48

会计年度:2018-06-30 
项目名称主营业务收入主营业务成本主营业务毛利毛利率
合计135,124,241.4465,776,731.3969,347,510.0551.32
其他(补充)691,037.73392,588.38298,449.3543.19
实验动物及附属产品销售业务3,019,541.802,139,292.86880,248.9429.15
药物临床前研究服务131,413,661.9163,244,850.1568,168,811.7651.87

会计年度:2017-12-31 
项目名称主营业务收入主营业务成本主营业务毛利毛利率
合计300,760,097.31130,859,717.36169,900,379.9556.49
实验动物及附属产品销售业务9,009,790.004,573,780.984,436,009.0249.24
药物临床前研究服务291,750,307.31126,285,936.38165,464,370.9356.71

    2/2 转到